Progyny (NASDAQ:PGNY) Updates FY 2026 Earnings Guidance
by Renee Jackson · The Cerbat GemProgyny (NASDAQ:PGNY – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.980-2.09 for the period, compared to the consensus earnings per share estimate of 1.740. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Progyny also updated its Q2 2026 guidance to 0.500-0.53 EPS.
Progyny Stock Performance
PGNY stock traded up $0.46 during mid-day trading on Thursday, hitting $19.16. The company had a trading volume of 1,827,030 shares, compared to its average volume of 1,371,456. The firm has a market cap of $1.50 billion, a PE ratio of 29.48, a price-to-earnings-growth ratio of 1.08 and a beta of 0.91. Progyny has a 12 month low of $16.10 and a 12 month high of $28.75. The stock’s fifty day moving average price is $17.87 and its two-hundred day moving average price is $21.69.
Progyny (NASDAQ:PGNY – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.44 by ($0.15). The company had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.47 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The business’s revenue was down 26.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Equities analysts anticipate that Progyny will post 1.12 earnings per share for the current year.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on the stock. JPMorgan Chase & Co. set a $35.00 price target on shares of Progyny in a research report on Wednesday, January 21st. Barclays lowered their price target on shares of Progyny from $29.00 to $23.00 and set an “overweight” rating on the stock in a research report on Friday, March 20th. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. KeyCorp lowered their price target on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Finally, Citigroup raised shares of Progyny to an “outperform” rating in a research report on Tuesday, January 20th. Nine investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $27.91.
Read Our Latest Research Report on Progyny
Insiders Place Their Bets
In related news, EVP Allison Swartz sold 4,657 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the sale, the executive vice president owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. This represents a 4.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 7,455 shares of company stock worth $129,515. Corporate insiders own 9.90% of the company’s stock.
Progyny News Summary
Here are the key news stories impacting Progyny this week:
- Positive Sentiment: Management raised guidance: Q2 EPS guided to $0.50–$0.53 (above the ~$0.44 consensus) and FY‑2026 EPS guided to $1.98–$2.09 (above the ~$1.74 consensus); Q2 revenue guided to $342–$355M. Strong guidance typically supports higher stock valuation as it implies better-than-expected future profitability. Progyny, Inc. Announces First Quarter 2026 Results
- Positive Sentiment: Share buybacks: the company disclosed repurchasing 8.8 million shares to date since November, which reduces float and can boost EPS and share price over time. Progyny, Inc. Announces First Quarter 2026 Results
- Neutral Sentiment: Some outlets (Zacks) reported an EPS beat (reported $0.50 vs. Zacks consensus $0.44), which supports the narrative of better-than-expected performance — this may reflect adjusted/non‑GAAP figures. Investors should confirm whether figures are GAAP or adjusted. Progyny (PGNY) Q1 Earnings and Revenues Beat Estimates
- Negative Sentiment: Reported GAAP results were weak: another report shows Q1 GAAP EPS of $0.29, missing the ~$0.44 consensus, and revenue ($328.5M) was down ~26% year‑over‑year. A GAAP miss and meaningful revenue decline can limit upside and raise questions about near‑term growth sustainability. Progyny Q1 earnings report / transcript
Hedge Funds Weigh In On Progyny
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd bought a new stake in Progyny during the fourth quarter worth about $25,000. Canada Pension Plan Investment Board bought a new position in shares of Progyny during the 2nd quarter valued at about $77,000. Quarry LP increased its position in shares of Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after purchasing an additional 3,427 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Progyny by 203.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock valued at $154,000 after purchasing an additional 4,708 shares during the last quarter. Finally, Entropy Technologies LP bought a new position in shares of Progyny during the 4th quarter valued at about $203,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.
About Progyny
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.